ReviewCurrent medicinal chemistry2012

Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

J Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.